Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian G Feagan

Showing results (31-40 of 464) with videos related to

Pageof 47
Sort By:
Digestive Diseases (Basel, Switzerland)|September 15, 2015
Targeting Leukocyte Trafficking in Inflammatory Bowel Disease: What Is the Clinical Evidence?Reena Khanna, Mahmoud H Mosli, Brian G Feagan
Digestive Diseases (Basel, Switzerland)|March 17, 2016
Anti-Integrins in Ulcerative Colitis and Crohn's Disease: What Is Their Place?Reena Khanna, Mahmoud H Mosli, Brian G Feagan
Digestive Diseases (Basel, Switzerland)|September 14, 2013
Challenging question: is treating inflammatory bowel disease an art or strictly an evidence-based matter?Reena Khanna, Mahmoud H Mosli, Brian G Feagan
Inflammatory Bowel Diseases|July 2, 2013
Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviewsBrian G Feagan, Nilesh Chande, John K MacDonald
Gut|October 15, 2011
Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a changeIngrid Ordás, Brian G Feagan, William J Sandborn
Alimentary Pharmacology & Therapeutics|January 17, 2020
Editorial: histologic normalisation in ulcerative colitisRish K Pai, Vipul Jairath, Brian G Feagan
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 21, 2012
Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel diseaseIngrid Ordás, Brian G Feagan, William J Sandborn
Drugs|January 24, 2014
T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospectsMahmoud H Mosli, Jesus Rivera-Nieves, Brian G Feagan
Expert Opinion on Investigational Drugs|July 31, 2018
Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn's diseaseChristopher Ma, Vipul Jairath, Reena Khanna, et al.
Gastroenterology & Hepatology|May 4, 2022
Janus Kinase Inhibitors for the Management of Patients With Inflammatory Bowel DiseaseRocio Sedano, Christopher Ma, Vipul Jairath, et al.
Pageof 47

Showing results (31-40 of 464) with videos related to

Sort By:
Pageof 47
Digestive Diseases (Basel, Switzerland)|September 15, 2015
Targeting Leukocyte Trafficking in Inflammatory Bowel Disease: What Is the Clinical Evidence?Reena Khanna, Mahmoud H Mosli, Brian G Feagan
Digestive Diseases (Basel, Switzerland)|March 17, 2016
Anti-Integrins in Ulcerative Colitis and Crohn's Disease: What Is Their Place?Reena Khanna, Mahmoud H Mosli, Brian G Feagan
Digestive Diseases (Basel, Switzerland)|September 14, 2013
Challenging question: is treating inflammatory bowel disease an art or strictly an evidence-based matter?Reena Khanna, Mahmoud H Mosli, Brian G Feagan
Inflammatory Bowel Diseases|July 2, 2013
Are there any differences in the efficacy and safety of different formulations of Oral 5-ASA used for induction and maintenance of remission in ulcerative colitis? evidence from cochrane reviewsBrian G Feagan, Nilesh Chande, John K MacDonald
Gut|October 15, 2011
Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a changeIngrid Ordás, Brian G Feagan, William J Sandborn
Alimentary Pharmacology & Therapeutics|January 17, 2020
Editorial: histologic normalisation in ulcerative colitisRish K Pai, Vipul Jairath, Brian G Feagan
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|July 21, 2012
Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel diseaseIngrid Ordás, Brian G Feagan, William J Sandborn
Drugs|January 24, 2014
T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospectsMahmoud H Mosli, Jesus Rivera-Nieves, Brian G Feagan
Expert Opinion on Investigational Drugs|July 31, 2018
Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn's diseaseChristopher Ma, Vipul Jairath, Reena Khanna, et al.
Gastroenterology & Hepatology|May 4, 2022
Janus Kinase Inhibitors for the Management of Patients With Inflammatory Bowel DiseaseRocio Sedano, Christopher Ma, Vipul Jairath, et al.
Pageof 47